Abstract In up to 30 % of patients with colorectal adenomatous polyposis, no germline mutation in the known genes APC, causing familial adenomatous polyposis, MUTYH, causing MUTYH-associated polyposis, and POLE or POLD1, causing Polymerase-Proofreading-associated polyposis can be identified, although a hereditary etiology is likely. To uncover new causative genes, exome sequencing was performed using DNA from leukocytes and a total of 12 colorectal adenomas from seven unrelated patients with unexplained sporadic adenomatous polyposis. For data analysis and variant filtering, an established bioinformatics pipeline including in-house tools was applied. Variants were filtered for rare truncating point mutations and copy-number variants assuming a dominant, recessive, or tumor suppressor model of inheritance. Subsequently, targeted sequence analysis of the most promising candidate genes was performed in a validation cohort of 191 unrelated patients. All relevant variants were validated by Sanger sequencing. The analysis of exome sequencing data resulted in the identification of rare lossof-function germline mutations in three promising candidate genes (DSC2, PIEZO1, ZSWIM7). In the validation cohort, further variants predicted to be pathogenic were identified in DSC2 and PIEZO1. According to the somatic mutation spectra, the adenomas in this patient cohort follow the classical pathways of colorectal tumorigenesis. The 
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Introduction
To date, three inherited monogenic forms of colorectal adenomatous polyposis syndromes can be delineated by molecular genetic analyses: (1) [6] ; and (3) autosomal dominant Polymerase-Proofreading-associated polyposis (PPAP), caused by specific germline missense mutations in the polymerase genes POLE and POLD1 [7, 8] . Recently, a homozygous loss-of-function germline mutation in the NTHL1 gene has been identified as rare predisposition to adenomatous polyposis and colorectal cancer (CRC) [9] . In up to 30 % of polyposis patients, no underlying germline mutation is identified, although a hereditary basis is likely. Currently, exome sequencing is considered the most powerful tool for the identification of new causative genes in Mendelian disorders of unknown etiology [10] . The underlying strategies include screening for recurrently mutated genes (overlap strategy), the biallelic hit strategy for a suspected recessive inheritance, and the tumor suppressor model in cancer predisposition syndromes (selection of genes which harbor both a heterozygous truncating germline mutation and a somatic mutation).
To uncover novel causative genes for adenomatous polyposis, the germline and tumor exomes of seven unrelated patients with unexplained disease were sequenced. Subsequently, a targeted mutation screening of the most promising candidate genes was performed in a large validation cohort. The identification of underlying genetic factors will provide insights into disease mechanisms, biological pathways, and potential therapeutic targets.
Materials and methods

Patients/data collection
All patients in the present study had unexplained colorectal adenomatous polyposis, i.e. no germline mutation in the APC or MUTYH genes was identified by Sanger sequencing of the coding regions, deletion/duplication analysis using Multiplex ligation-dependent probe amplification (MLPA), and screening for pathogenic deep intronic APC mutations [5, 11] . Furthermore, neither of the two hotspot mutations in POLE and POLD1 was present [8] . In addition, in all patients a SNP array-based CNV analysis was performed, as described elsewhere [12] .
Exome sequencing was performed in a discovery cohort of seven unrelated index patients. For targeted analysis of candidate genes, a validation cohort of 191 unrelated index polyposis patients was used. The inclusion criteria for both the discovery and validation cohort were the presence of at least 20 synchronous or 40 metachronous, histologically confirmed colorectal adenomas, irrespective of inheritance pattern and extra intestinal lesions. All patients were of central European origin according to family name and self-reporting. Relatives were only considered to be affected if their medical records confirmed fulfilment of the inclusion criteria. The study was approved by the local ethics review board (Medical Faculty of the University of Bonn, board no. 224/07), and all patients provided written informed consent prior to inclusion.
High-throughput sequencing and bioinformatics workflow
Genomic leukocyte DNA was extracted from peripheral EDTA-anticoagulated blood samples using the standard salting-out procedure. Tumor DNA was extracted from punches of colorectal formalin-fixed and paraffin-embedded (FFPE) tumor tissue, as described elsewhere [13] .
Library preparation and whole exome target enrichment was performed according to Agilent's SureSelect protocol (Human All Exon 50 Mb v2, 2011). Multiplexed paired-end sequencing was performed on the Illumina HiSeq 2000 platform in accordance with the manufacturer's protocol. Base calling and demultiplexing were performed using Illumina's CASAVA pipeline v1.7. Raw reads were mapped to GRCh37/ hg19 using BWA v0.5.8 [14] with default parameters. Local realignment, quality value recalibration, and variant calling were performed using GATK v2.1-8 [15] . In-house tools and ANNOVAR [16] were used to annotate and filter the variants. Metrics and enrichment statistics were calculated with Picard using Agilent's SureSelect target regions.
Filtering was then performed to identify germline truncating variants (nonsense mutations, frameshift deletions/ insertions, and mutations at highly conserved splice sites) which were afterwards selected according to a recessive (biallelic mutations) or a dominant (heterozygous mutations) mode of inheritance. In addition, screening was performed for genes with both a heterozygous truncating germline variant and a second (somatic) mutation of the wildtype allele in the respective tumor sample (tumor suppressor model). Frequent alterations were excluded (minor allele frequency (MAF) C0.03 for the recessive model and C0.01 for the dominant model, based on data from dbSNP, The 1000GenomesProject, and the Exome Variant Server). In addition to truncating variants, missense variants of the candidate genes were selected for MAF\0.001 and deleterious effect, as predicted by at least two of three in silico prediction tools (PolyPhen-2, MutationTaster, and SIFT). Detailed visual inspection of the remaining variants in a read browser (Integrative Genomics Viewer) was done to exclude obvious sequencing artifacts.
To screen for point mutations of the most promising candidate genes, targeted next generation sequencing (NGS) was performed using TruSeq enrichment protocols on an Illumina HiSeq 2000 sequencer (Illumina, San Diego, USA), as described previously [8] .
For data analysis, the Varbank pipeline version 2.6 and the Cartagenia BENCHlab NGS platform version 3.0.4 (Leuven, Belgium) were used. Splicing efficiencies of normal and mutant sequences were calculated using the splice prediction program NNSPLICE 0.9 from BDGP (the Berkeley Drosophila Genome Project). The expression of candidate genes in both normal and tumor colorectal tissue was checked by means of the EST profiles provided in Unigene. The etiological relevance of the mutations was further explored by evaluating their genetic intolerance to functional variation according to the Residual Variation Intolerance score (RVIS) [17] and the likelihood of haploinsufficiency according to the Haploinsufficiency Score [18] .
The exome sequencing data of colorectal adenoma samples were screened for somatic mutations in known adenoma and colorectal cancer genes. The variants were selected for truncating variants (nonsense mutations, frameshift deletions/insertions, and mutations at highly conserved splice sites) and missense variants with a predicted deleterious effect by at least one of two in silico prediction tools (PolyPhen-2 and SIFT) and a MAF B 0.01. Only variants with a read depth (coverage) of [109 and a fraction of mutated reads [10 % were considered. For filtering the VariantStudio software (Illumina) was used.
Sanger sequencing
The identified variants were validated by Sanger sequencing of the corresponding region using standard protocols (primer sequences available upon request). The results were analyzed with the SeqPilot software (JSI Medical Systems).
Frequency of colorectal tumors with somatic mutations in candidate genes
Data concerning the frequency (percentage) of colorectal tumors with somatic mutations in the candidate genes were obtained from the exome database of The Cancer Genome Atlas (TCGA): Somatic variants identified in exome data from colonic (n = 273) and rectal (n = 116) adenocarcinomas were downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). To correct the data for the presence of passenger mutations, hypermutated tumors were excluded from the dataset. Therefore, the distribution of somatic variants in the TCGA exomes were analyzed and all tumors with [200 variants (24 % of the tumors) were excluded [12] . The remaining 295 exomes (76 % of tumors) were used to calculate the frequency of tumors with somatic mutations in the candidate genes.
Results
All seven patients in the discovery cohort presented with an attenuated colorectal phenotype and without evident extracolonic lesions or a conspicuous family history (sporadic or isolated cases). The basic clinical features of the discovery cohort are summarized in Suppl. Table S1 . Our validation cohort consisted of 191 unrelated patients with the same phenotype and inclusion criteria (Suppl . Table S2 ).
In the discovery cohort, the mean on-target coverage of mapped reads was 579, and 83 % of bases were covered at C109. A total of 151,966 variants were called in the coding regions of the exome sequencing data. The overall performance of exome sequencing is shown in Suppl. Table S3 .
No pathogenic germline mutation in known polyposis genes including the recently described NTHL1 [8] was found. According to the tumor suppressor model no potential candidate gene could be identified. Afterwards, a number of stringent filter steps were applied to select for rare, truncating variants (Fig. 1) , and obvious false positive results (artifacts) were excluded through detailed visual inspection. This approach identified two genes which were apparently affected by two truncating variants in at least one patient, indicating biallelic alterations (recessive model), and one gene which was affected by truncating heterozygous variants (dominant model) in at least two patients.
In the two genes consistent with a recessive model (PIEZO1 and ZSWIM7), each of the variants was identified in one patient and appeared to be homozygous. In the gene Novel candidate genes in adenomatous polyposis 283
consistent with a dominant model (DSC2), both patients carried the same frameshift mutation (Table 1) . Data mining according to function, pathways, and expression in colorectal tissue demonstrated that these three genes are involved in cell adhesion, proliferation, or recombination repair (Table 2 ). In none of these candidate genes a second hit could be detected in the corresponding colorectal tumor samples. No further candidate genes were identified through the inclusion of validated germline CNVs, i.e. if large deletions or partial duplications were considered as a second mutation in a certain gene in one patient (recessive model), or an additional heterozygous mutation in a second patient (dominant model). Sanger sequencing of leukocyte DNA confirmed the variants in DSC2 and ZSWIM7 (Suppl. Fig. 1 and 2 ) whereas the variant in PIEZO1 appeared heterozygous instead of homozygous which might be explained by the low read depth (79) of this region (Suppl. Figure 3) . However, in view of its interesting function, the variant was included in further analyses. In the discovery cohort, no missense variants in these three genes met the filter criteria and no putative pathogenic somatic point mutation (''second hit'') was detected in tumor tissue while the germline mutation (''first hit'') could be confirmed in all available colorectal adenomas of three patients (Suppl .   Table S4 ). Unfortunately, no blood samples from relatives were available for a segregation analysis.
Subsequently, a validation cohort of 191 unrelated patients was screened for additional germline point mutations in the three promising candidate genes. In patient F807, the same DSC2 frameshift mutation described above was detected. No other truncating mutation was found in any of the three genes. In total, six different heterozygous rare (MAF \0.001) missense variants, predicted to have deleterious effects by at least two of three in silico prediction tools, were identified (two missense variants in DSC2 in three patients; and four unique missense variants in PIEZO1) ( Table 1 and Suppl. Table S5 ). In ZSWIM7, no additional mutations meeting the filter criteria were found. No large deletions or partial duplications were detected in any of the three candidate genes.
In the families of two patients from the validation cohort (F386 and F807) with different DSC2 mutations, analysis of affected and apparently unaffected relatives was possible (Suppl . Table S5 ). However, segregation of the variant with the phenotype was either excluded (F386), or could not be confirmed (F807).
To evaluate the functional relevance of these three candidate genes in more detail, they were examined for: (1) the occurrence of somatic mutations in colorectal tumors (TCGA exome data); (2) their genetic intolerance to functional variation (Intolerance score according to Petrovski [17] ) and (3) the likelihood of haploinsufficiency (haploinsufficiency score according to Huang [18] ). In none of the genes a high frequency ([3 %) of somatic mutations in 295 non-hypermutated colorectal tumors could be detected (Table 2 ). DSC2 showed a low (negative) RVIS (-1.85 to -0.55, corresponding to values \25th percentile). This reflects high intolerance to genetic variation, which in turn indicates that this gene is subject to purifying selection. For DSC2, the haploinsufficiency score, which indicates dosagesensitive genes, was also reduced (\20 %) ( Table 2 ).
In addition, the exome sequencing data of 12 colorectal adenomas from five patients of the discovery cohort were filtered for potential pathogenic somatic mutations in 22 known adenoma and CRC driver genes (Suppl . Table S6 ). Pathogenic or likely pathogenic mutations could be identified in 10/12 samples (Suppl . Table S7 ). There was no evidence for the presence of APC mosaicism (i.e., in none of the patients the same APC mutation could be detected in different adenoma samples). In each of three adenoma samples, two different APC mutations could be identified and in each of two samples one APC mutation. In three and two samples, respectively, CTNNB1 and KRAS mutations (codon 12 and 13) could be detected. In all those samples no APC mutation was identified. FBXW7, MSH2, and TP53 mutations were found in addition to APC or KRAS mutations. 
Discussion
In a number of patients with colorectal adenomatous polyposis, no germline mutation in the known causal genes can be identified. Although the syn-or metachronous occurrence of dozens to hundreds of adenomas is strongly suggestive of an underlying hereditary basis, it remains unclear so far, whether the predisposing genetic factors mainly act in a monogenic fashion, or contribute as low or moderately penetrant variants to a more complex, oligo/ polygenic trait.
To uncover novel, potentially causative genes, exome sequencing of leukocyte and tumor DNA was performed in a discovery cohort of seven unrelated patients with histologically confirmed, genetically unexplained adenomatous polyposis (minimum of 50 adenomas). The findings were then confirmed in a large validation cohort. According to the observed somatic mutation spectra, the adenomas in this patient cohort follow the classical pathways of colorectal tumorigenesis [19] .
Assuming a monogenic mode of inheritance and high penetrance, the frequency of causative germline mutations With the exception of the mutation in ZSWIM7, all mutations were heterozygous EVS Exome Variant Server, MAF minor allele frequency, NA not available, TGP 1000 Genomes Project a Data from exome sequenced colon and rectum adenocarcinomas of the Cancer Genome Atlas (TCGA) database: number of tumors with somatic mutations/total number of non-hypermutated tumors. Non-hypermutated tumors are defined as those with \200 somatic mutations per tumor (n = 295) [12] NA not available, RVIS Residual Variation Intolerance Score
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in the general population is expected to be low. By applying an established stringent filter workflow, including comparisons with large control cohorts, we identified in four of the seven patients unique (i.e. not present in controls) or rare (i.e. frequency \1 % for dominant model or \3 % for recessive model in controls), potentially pathogenic germline variants in three protein coding genes (DSC2, ZSWIM7, PIEZO1) with molecular and cellular functions related to tumorigenesis. In two of these three genes, additional variants with predicted pathogenicity were detected in the validation cohort. The cadherin superfamily member Desmocollin 2 (DSC2) is a critical component of desmosomes within the intestinal epithelium, and is thus involved in cell adhesion [20] . In colorectal cancer (CRC), decreased expression of DSC1-3 is significantly correlated with higher tumor grading [21] . Another study has shown that loss of DSC2 results in proliferation of colonic epithelial cells through the activation of Akt/b-catenin signaling [22] . Furthermore, DSC2 has been described in various other cancer types (lung, breast, urothelial, gastric, pancreatic ductal adenocarcinoma). The only truncating variant in DSC2 identified in the present study was a frameshift mutation, which was detected in three patients. This and another of the three DSC2 mutations found in our cohort have also been detected in patients with (arrhythmogenic right ventricular) cardiomyopathy (Suppl . Table S5 ), however, it is unknown whether these patients had any history of colonoscopy or gastrointestinal symptoms.
We identified probably pathogenic DSC2 germline variants in 3 % of our patients. According to the known function and involved pathway, and the results of functional and in silico prediction tools, it is likely that the gene contributes in colorectal adenoma formation. However, the occurrence of 2/3 variants in normal controls at a very low frequency and the results of segregation analysis argues more in favor that DSC2 mutations act as moderately penetrant risk factors rather than as highly penetrant mutations.
ZSWIM7 or SWS1 is part of a complex which plays an important role in the homologous recombination pathway [23] . Within this complex, SWS1 interacts with RAD51D. The authors demonstrated that the knockdown of SWS1 reduces the number of cells with RAD51 foci, and that the SWIM domain is essential for the prorecombinogenic function of SWS1. The frameshift deletion in patient F710 is located within the SWIM-type Zinc finger domain. The very low frequency of the frameshift mutation identified in our patient in normal controls is consistent with the assumption of a recessive mode of inheritance.
Probably pathogenic PIEZO1 germline variants were detected in 2.5 % of our patients. Knockdown of the multitransmembrane domain protein PIEZO1 (also known as FAM38A) in epithelial cells has been shown to result in reduced cell adhesion and increased cell migration and metastasis in lung tumors [24] . It could be shown that a knockdown of the PIEZO1 channel in zebrafish leads to the formation of epithelial cell masses by preventing the extrusion of supernumerary cells [25] . The authors also described the extrusion of living cells at colon surfaces. This suggests that a loss of PIEZO1 in colon tissue could lead to polyp formation. According to a recent study, haploinsufficiency of PIEZO1 leads to endothelial abnormality, indicating the importance of this gene for vascular structure [26] . PIEZO1 mutations have also been described in patients with dehydrated hereditary stomatocytosis/ hereditary xerocytosis [27] . However, the specific positions of these mutations differ from those observed in the present cohort, and so far, only missense and inframe variants have been reported.
Evaluation of the clinical relevance of germline variants identified in high-throughput experiments is challenging [28] , particularly in the absence of recurrently mutated genes and when segregation data are inconsistent or lacking. Previous and the present data are consistent with the observation that newly identified monogenic subtypes of inherited tumor predisposition syndromes are very rare. At least some of the unexplained tumor syndromes appear to show extreme genetic heterogeneity, and large patient cohorts are therefore required to validate candidate genes through the identification of recurrent germline mutations.
The present analyses might have missed some mutations in the targeted exomes since some variants are not identified easily with currently available sequencing techniques (e.g. within repeat tracts in coding sequences) or due to low coverage of certain genomic regions. Moreover, some causative mutations might be located outside the targeted exome, e.g. in non-coding regions or unannotated genes.
In conclusion, the known functions of DSC2, PIEZO1 and ZSWIM7 render these genes interesting candidates, however, their causal and clinical relevance have to be further explored in larger cohorts. 
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